Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
AMG 319
Другие языки:

    AMG 319

    Подписчиков: 0, рейтинг: 0
    AMG 319
    AMG319.svg
    Clinical data
    ATC code
    • None
    Legal status
    Legal status
    • Investigational
    Identifiers
    • (S)-N-(1-[7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl]ethyl)-9H-purin-6-amine
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C21H16FN7
    Molar mass 385.396 g·mol−1
    3D model (JSmol)
    • C[C@@H](c1cc2ccc(cc2nc1c3ccccn3)F)Nc4c5c([nH]cn5)ncn4
    • InChI=1S/C21H16FN7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12H,1H3,(H2,24,25,26,27,28)/t12-/m0/s1
    • Key:KWRYMZHCQIOOEB-LBPRGKRZSA-N

    AMG 319 is a drug developed by Amgen which acts as an inhibitor of the phosphoinositide 3-kinase enzyme subtype PI3Kδ. It was originally developed as an anti-inflammatory drug with potential applications in the treatment of autoimmune conditions such as rheumatoid arthritis, but subsequent research showed that it inhibits cell proliferation and might potentially have useful anti-cancer effects, and it has been put into clinical trials to assess its safety and tolerability in this application.

    Mechanism(s) of action

    It is a potential immunotherapy because blocking PI3Kδ (PI3K p110δ) eliminates a group of inhibitory immune cells and may allow the immune system to better attack the cancer cells.p110δ inactivation in regulatory T  cells unleashes CD8+cytotoxic T  cells.

    Clinical trials

    Its first clinical trial was a phase I/II study in adults with relapsed or refractory lymphoid malignancies. This was due to run from 2011 to 2013.

    In 2015/16 it started a phase II clinical trial as a neoadjuvant therapy for human papillomavirus (HPV) negative head and neck squamous-cell carcinoma (HNSCC) (prior to resection surgery).

    See also


    Новое сообщение